A new Michigan Medicine study finds that nearly half of early-stage breast cancer patients opt to extend endocrine therapy beyond five years, often seeking extra peace of mind. Younger patients and those with prior chemotherapy are more likely to continue treatment. Read on to discover how U-M is advancing personalized care through these insights.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.